Related Experiment Video
Updated: Mar 19, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Epithelial TMPRSS2 impairs glucose homeostasis in obese mice by regulating ghrelin-GLP-1 receptor signaling pathway
Dilraj Kaur1, Sagarika Chakrabarty2, Claudius Witzler1
1Center for Thrombosis and Hemostasis (CTH), Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
Abstract:
Glucagon-like peptide-1 (GLP-1) and glucose-induced insulinotropic polypeptide (GIP) receptor agonists have revolutionized obesity therapy, but causes of obesity-associated dysregulation of endogenous incretin production remain incompletely understood. Here we show that intestinal transmembrane serine protease 2 (TMPRSS2) plays a pivotal role in deregulating anti-diabetic GLP-1 production in obesity. TMPRSS2 is widely coexpressed in intestinal epithelial cells along with its signaling target protease-activated receptor 2 (PAR2). In addition to its role in regulating coagulation protease-mediated adipose tissue inflammation, PAR2 signaling in the gut controls postprandial GIP secretion. TMPRSS2, but not the epithelial cell-expressed proteases FXa or matriptase, activates PAR2 and thereby promotes postprandial GIP release. Accordingly, a PAR2-mutant mouse resistant to TMPRSS2 cleavage is protected from GIP upregulation and diet-induced obesity. In the context of obesity, TMPRSS2 also attenuates bioavailability of the ghrelin pathway and thereby suppresses GLP-1-mediated control of glucose homeostasis. Pharmacological inhibition or genetic deletion of TMPRSS2 restores ghrelin signaling-dependent GLP-1 secretion and GLP-1's anti-diabetic effects on nutritional glucose homeostasis. Thus, epithelial cell-expressed TMPRSS2, which critically contributes to the lung pathology in SARS-CoV-2 infection, emerges as an intestinal incretin regulator and a potential link between infection and chronic cardiometabolic diseases.
Insights
Transmembrane serine protease 2 (TMPRSS2) in the gut deregulates incretin production, worsening obesity and glucose control. Inhibiting TMPRSS2 restores incretin signaling, offering a potential therapeutic target for obesity and related metabolic diseases.
Area of Science:
- Gastroenterology
- Metabolic Diseases
- Molecular Biology
Background:
- Glucagon-like peptide-1 (GLP-1) and glucose-induced insulinotropic polypeptide (GIP) receptor agonists are effective obesity treatments, but the causes of altered endogenous incretin production in obesity are unclear.
- Intestinal epithelial cells (IECs) express proteases like TMPRSS2 and its target PAR2, which are implicated in metabolic regulation and inflammation.
Purpose of the Study:
- To investigate the role of intestinal transmembrane serine protease 2 (TMPRSS2) in regulating endogenous incretin production and its impact on obesity and glucose homeostasis.
- To explore TMPRSS2's mechanism of action via protease activated receptor 2 (PAR2) signaling in the gut.
Main Methods:
- Utilized a PAR2 mutant mouse model resistant to TMPRSS2 cleavage.
- Investigated the effects of pharmacological inhibition and genetic deletion of TMPRSS2 on incretin secretion and glucose homeostasis.
- Assessed the impact of TMPRSS2 on ghrelin pathway bioavailability and GLP-1 signaling.
Main Results:
- TMPRSS2 activates PAR2 in the gut, promoting postprandial GIP release and contributing to diet-induced obesity.
- A PAR2 mutant mouse model resistant to TMPRSS2 was protected from GIP upregulation and obesity.
- In obesity, TMPRSS2 impairs ghrelin pathway bioavailability, suppressing GLP-1 secretion and its glucose-lowering effects.
- Inhibition or deletion of TMPRSS2 restored ghrelin-dependent GLP-1 secretion and anti-diabetic effects.
Conclusions:
- Epithelial TMPRSS2 is a key regulator of intestinal incretins (GLP-1 and GIP), influencing obesity and glucose homeostasis.
- TMPRSS2 represents a potential therapeutic target for metabolic diseases, linking gut health, infection (e.g., SARS-CoV-2), and cardiometabolic disorders.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Cell Specific Gene Expression
Insulin: The Receptor and Signaling Pathways
Obesity
Regulation of Food Intake
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...

